<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059069</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0349</org_study_id>
    <nct_id>NCT03059069</nct_id>
  </id_info>
  <brief_title>The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients</brief_title>
  <official_title>The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on&#xD;
      depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive&#xD;
      mood could be influence the patient's quality of life and glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of depressive disorder is higher in individuals with chronic diseases, and the&#xD;
      screening and management of depression is emphasized. Diabetes mellitus (DM) is a class of&#xD;
      chronic disease and the incidence of DM has been increasing. According to previous study,&#xD;
      31.1% of patients with DM accompanied with depressive disorders which was higher than that of&#xD;
      subjects without DM. Furthermore, DM as well as depression is known for risk factor for&#xD;
      dementia.&#xD;
&#xD;
      The choline metabolism involves in neuropathology of depressive disorders and individuals&#xD;
      with depressive disorders showed the lower level of choline concentration. Choline&#xD;
      alphoscerate is cholinergic precursor and showed the favorable clinical results in dementia&#xD;
      management.&#xD;
&#xD;
      As pseudodementia can be presented as depressive disorder and choline alphoscerate would be&#xD;
      an option for these cases. Therefore, the aim of this study is to investigate the effect of&#xD;
      Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and&#xD;
      demonstrate the impact of improved depressive mood could be influence the patient's quality&#xD;
      of life and glycemic control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>6 months after the treatment</time_frame>
    <description>The HDRS will be scored by face-to-face interview.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in Mini-mental state examination (MMSE) score</measure>
    <time_frame>6 months after the treatment</time_frame>
    <description>MMSE questionnaire will be checked by careful interview and self-reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type2 Diabetes With Depressive Mood</condition>
  <arm_group>
    <arm_group_label>Glitamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>same shape, color, size tablet as Glitamin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chonline Alphoscerate</intervention_name>
    <description>Patients treated with Chonline Alphoscerate as add on therapy to their medication</description>
    <arm_group_label>Glitamin</arm_group_label>
    <other_name>Gliatamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Patients maintain their medication with either Gliatamin or placebo for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetic patients&#xD;
&#xD;
          -  Age ≥ 50&#xD;
&#xD;
          -  Glycemic control: HbA1c ≤ 10.0%&#xD;
&#xD;
          -  10 ≤ Beck Depression Inventory (BDI) &lt;30 points&#xD;
&#xD;
          -  Participants who can undergo contraception in case of being in childbearing period&#xD;
&#xD;
          -  Understands the study procedure, alternatives, and risks and voluntarily agrees to&#xD;
             participate by giving written informed concent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes, Secondary diabetes, gestational diabetes&#xD;
&#xD;
          -  Ongoing dementia treatment or anti-depressive disorder medication&#xD;
&#xD;
          -  Uncontrolled psychiatric disorder&#xD;
&#xD;
          -  BDI ≥ 30 points&#xD;
&#xD;
          -  Heavy alcoholics&#xD;
&#xD;
          -  Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, autoimmune&#xD;
             liver disease, liver cirrhosis, chronic viral hepatitis)&#xD;
&#xD;
          -  Allergy or hypersensitivity to target medication or any of its components&#xD;
&#xD;
          -  Renal failure, moderate or severe renal impairment (estimated glomerular filtration&#xD;
             rate &lt; 30 mL/min/1.73 m2), or ongoing dialysis&#xD;
&#xD;
          -  Abnormal liver function (AST/ALT &gt; x3 upper normal limit)&#xD;
&#xD;
          -  History of alcohol or drug abuse in the previous 3 months&#xD;
&#xD;
          -  Premenopausal women who are nursing or pregnant&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) or human immunodeficiency virus (AIDS)&#xD;
&#xD;
          -  chronic pancreatitis or pancreatic cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bong-Soo Cha, MD, Ph.D</last_name>
    <phone>82-2-2228-5457</phone>
    <email>bscha@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong Soo Cha, MD</last_name>
      <phone>+82-2-2228-1932</phone>
      <email>bscha@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

